

### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

5/6/2013; Page 1

Т

Suggested Formula	Simethicone 40 mg/mL Oral Liquid (Suspension, 50 mL)	FIN	F 002 531v2
----------------------	--	-----	-------------

## SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Simethicone, USP	2.000	g				
Cellulose (Microcrystalline), NF	4.00	g				
Polysorbate 80, NF	2.0	mL				
Medisca Oral Suspend (Suspending Vehicle)	25.0	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 50.0	mL	Ś			

# SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information		S		
Hygroscopic (protect from moi	sture whenever possible):	Polysorbate 80, Cellulose		
Light Sensitive (protect from li	ght whenever possible):	Polysorbate 80		
Oxygen Sensitive (protect from	n oxygen whenever possible):	Polysorbate 80		
Suggested Preparatory Guidelines				
Non-Sterile Preparat	ion Sterile Preparation			
<u>Processing Error /</u> <u>Testing Considerations</u> :		considerations during preparation, it is suggested to the required quantities of ingredients.		
Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.				
This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.				



#### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

5/6/2013; Page 2

Suggested Formula	Simethicone 40 mg/mL Oral Liquid (Suspension, 50 mL)	FIN	F 002 531v2	
----------------------	--	-----	-------------	--

## SUGGESTED PREPARATION (for 50 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor <sup>(*)</sup> :	Processing Error	Qty. to measure
Simethicone, USP	2.000	g			
Cellulose (Microcrystalline), NF §	4.00	g			
Polysorbate 80, NF §	2.0	mL			
Medisca Oral Suspend (Suspending Vehicle)	25.0	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 50.0	mL	Y.C.		

§ Weigh / measure just prior to use.

\* Takes into account increased batch size conversions and density conversions, if required.

# **Preparatory Instruction** 1. **Powder-liquid preparation:** A. Combine and mix the following ingredients together to form a homogeneous paste-like dispersion: -Simethicone -Cellulose (Microcrystalline) B. Incrementally add the Polysorbate 80 to the homogeneous paste-like dispersion (Step 1A). End result: Homogeneous paste-like dispersion. 2. Medium integration: A. Incrementally add the homogeneous paste-like dispersion (Step 1B) to the Oral Suspend (Suspending Vehicle). Specifications: Continuously mix. End result: Homogeneous liquid-like dispersion. 3. **Filling to volume:** A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 2A) to fill to the required batch size (50.0 mL plus processing error adjustments). Specifications: Continuously mix. End result: Homogeneous liquid-like dispersion.



### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

5/6/2013; Page 3

	Suggested Formula	Simethicone 40 mg/mL Oral Liquid (Suspension, 50 mL)	FIN	F 002 531v2
_				

# 4. Product transfer:

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.

## SUGGESTED PRESENTATION

		14 days, refrigerated, as per USP.	Packa Requirem		<ul> <li>Tightly closed, light-resistant dispensing bottle.</li> <li>To be administered with a metered dose- measuring device.</li> </ul>
	1	Use as directed. Do not exceed dose.	l prescribed	5	Cap tightly after use.
	2	Keep out of reach of children.		6	Shake well before use.
Auxiliary Labels	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.		7	Keep refrigerated. Do not freeze.
	4	Protect from light.			
Pharmacist Instructions	Add any auxiliary labels specific to the active to the dispensing container as deemed necessary				
Patient Instructions	Contact your pharmacist in the event of adverse reactions				



#### MEDISCA<sup>®</sup> NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

5/6/2013; Page 4

	Sugges Form	Nimethicone /III mg/mL (Irg) Lightid (Nispension NLmL)	FIN	F 002 531v2					
REF	REFERENCES								
-		Cellulose, microcrystalline. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 4 <sup>th</sup> Edition. American Pharmaceutical Association; 2003: 108.							
1		Polyoxyethylene Sorbitan Fatty Acid Esters. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2003: 479.							
		Simethicone. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2003: 541.							
2		Simethicone (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 1768.							
-		USP <795>. United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 2457.							

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.